<DOC>
	<DOCNO>NCT00768131</DOCNO>
	<brief_summary>The purpose study determine EGFR status ( positive negative ) FISH predict response cetuximab therapy NSCLC patient treat carboplatin paclitaxel</brief_summary>
	<brief_title>A Study Determine Whether EGFR Status FISH Can Predict Results Non Small Cell Lung Cancer ( NSCLC ) Patients Treated With Cetuximab , Carboplatin Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects present Stage IV , Stage IIIB NSCLC recurrent disease follow radiation therapy surgical resection No prior chemotherapy antiEGFR target therapy Sufficient tumor material FISH test Measurable disease ( RECIST ) ECOG performance status 0 1 Symptomatic uncontrolled CNS metastasis Inadequate hematologic function define ANC &lt; 1,500/mm3 , platelet count &lt; 100,000/mm3 , hemoglobin level &lt; 9 g/dl Inadequate hepatic function define total bilirubin &gt; 1.25 x ULN , AST level &gt; 1.5 x ULN , alkaline phosphatase &gt; 5.0 x ULN Inadequate renal function define serum creatinine level &gt; 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>